Ingerman A, Broderick G, Williams R D, Carroll P R
Department of Urology, University of California, School of Medicine, San Francisco.
Urology. 1993 Nov;42(5):528-32. doi: 10.1016/0090-4295(93)90263-a.
Stage A1 (low-grade and low-volume) adenocarcinoma is associated with a low likelihood of progression. Repeat transurethral resection has been used to identify patients at increased risk (residual cancer noted) as well as those at low risk of progression (no residual cancer noted). We recently evaluated the ability of this technique to define a low-risk patient population. We reviewed the records of 24 patients who underwent repeat transurethral resection after they were identified as having Stage A1 prostatic cancer on initial resection (Gleason score < 5, tumor volume comprising < 5% of the resection specimen). Despite no evidence of residual carcinoma on repeat resection, 3 patients (13%) progressed at a mean follow-up of seven years (2 locally, 1 locally and distantly). We conclude that repeat resection does not effectively evaluate the risk of progression and that other techniques including transrectal ultrasonography and serial prostate-specific antigen measurements should be similarly evaluated.
A1期(低级别、小体积)腺癌进展的可能性较低。重复经尿道切除术已被用于识别进展风险增加的患者(发现残留癌)以及进展风险较低的患者(未发现残留癌)。我们最近评估了该技术定义低风险患者群体的能力。我们回顾了24例患者的记录,这些患者在初次切除时被诊断为A1期前列腺癌(Gleason评分<5,肿瘤体积占切除标本的<5%),之后接受了重复经尿道切除术。尽管重复切除时未发现残留癌的证据,但3例患者(13%)在平均7年的随访中出现了进展(2例为局部进展,1例为局部及远处进展)。我们得出结论,重复切除不能有效地评估进展风险,包括经直肠超声检查和连续前列腺特异性抗原测量在内的其他技术也应进行类似评估。